The FDA approved the combination of lenvatinib (Lenvima, Eisai) plus pembrolizumab (Keytruda, Merck) for first-line treatment of adult patients with advanced renal cell carcinoma (RCC).
“This approval is based, in part, on data demonstrating that [lenvatinib] plus [pembrolizumab] significantly reduced the risk of disease progression or death versus sunitinib,” said Robert Motzer, MD, the lead investigator on the CLEAR study, on which the approval is based. “This is a